Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey.

Department of Endocrinology and Metabolism Disease, Division of Internal Medicine, Ege University Hospital, Izmir, Turkey.
Journal of Assisted Reproduction and Genetics (Impact Factor: 1.77). 01/2009; 26(1):1-6. DOI: 10.1007/s10815-008-9280-8
Source: PubMed

ABSTRACT Dyslipidemia, cardiovascular disease and hypertension are more frequently seen in patients with PCOS than in normal patients. We aimed at evaluating the distribution of Apo E alleles that can influence cardiovascular risk of the PCOS patients and control subjects.
In this study, 129 young women with PCOS and 91 healthy women were included. In all subjects we performed hormonal, biochemical and Apo E genetic analysis.
The Apo E3 allele was found at a significantly higher frequency in the PCOS patient group compared with the control group. The Apo E2 allele was found at a significantly higher frequency in the control group compared with the patient group with PCOS.
Although there were genotype and allele differences between control and patient groups in this study, no statistically significant change was determined in lipid and other cardiovascular risk factors in connection with allele and genotype.

Download full-text


Available from: Buket Kosova, Jul 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes an algorithm of face image warping based on local constraints. Our method firstly specifies a limited number of feature points as the center of deformation, then finds their locations in transformed image and calculates their influencing radiuses respectively, after then calculates the geometric transformation of pixels within influencing areas according to local warping formula, finally calculates pixel gray values by means of bi-linear interpolation. Experimental results show that this approach is flexible, simple, fast and efficient.
    Signal Processing, 2004. Proceedings. ICSP '04. 2004 7th International Conference on; 01/2004
  • [Show abstract] [Hide abstract]
    ABSTRACT: To quantify the magnitude and pattern of low-density lipoprotein (LDL) cholesterol and nonhigh-density lipoprotein (HDL) cholesterol levels in women with polycystic ovary syndrome (PCOS) versus control women. Systematic review and meta-analysis of lipid levels in published cross-sectional studies worldwide where PCOS women and controls were examined and sampled. Differences in plasma lipids (including triglycerides, HDL-cholesterol, LDL-cholesterol, and nonHDL-cholesterol) in PCOS versus control subjects were calculated. Comparisons were made with and without body mass index (BMI) matching. Triglyceride levels were 26 mg/dL (95% confidence interval [CI] 17-35) higher and HDL-cholesterol concentrations 6 mg/dL (95% CI 4-9) lower in women with PCOS. Also, LDL-cholesterol and nonHDL-cholesterol concentrations were higher in PCOS: by 12 mg/dL (95% CI 10-16) and 19 mg/dL (95% CI 16-22), respectively. With BMI matching, LDL-cholesterol and nonHDL-cholesterol were still higher in PCOS: by 9 mg/dL (95% CI 6-12) and 16 mg/dL (95% CI 14-19), respectively. LDL-cholesterol and nonHDL-cholesterol differences were greater with National Institutes of Health criteria [15 mg/dL (95% CI 13-17) and 21 mg/dL (95% CI 16-25), respectively] versus Rotterdam criteria [8 mg/dL (95% CI 5-12) and 17 (95% CI 13-22), respectively]. Dyslipidemia is common in PCOS. Beyond known alterations in triglycerides and HDL-cholesterol, women with PCOS have higher LDL-cholesterol and nonHDL-cholesterol, regardless of BMI. We recommend that all women with PCOS be screened for dyslipidemia, including LDL-cholesterol and nonHDL-cholesterol determinations, for effective cardiovascular risk prevention.
    Fertility and sterility 03/2011; 95(3):1073-9.e1-11. DOI:10.1016/j.fertnstert.2010.12.027
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The relation between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD) remains unclear. In an attempt to provide high-quality evidence on the relation between PCOS and CVD, relevant literature for CVD risk markers [C-reactive protein (CRP), homocysteine (Hcy), tumor necrosis factor-alpha (TNF-α), plasminogen activator inhibitor-1 (PAI-1), lipoprotein (a) [Lp(a)], advanced glycation end-products (AGEs), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1) and fibrinogen] in women with PCOS was reviewed and analyzed. METHODS: A systematic search was conducted electronically using specific eligibility criteria. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated and combined appropriately. To ensure synthesis of the best available evidence, sensitivity analyses were performed. RESULTS A total of 130 data sets were included in 11 different outcomes, involving 7174 and 5076 CVD markers in women with PCOS and controls, respectively. Women with PCOS demonstrated significantly elevated CRP [WMD (95% CI) 0.99 (0.77-1.21)], Hcy [2.25 (1.46-3.03)], PAI-1 antigen [16.96 (7.25-26.28)], PAI-1 activity [0.71 (0.18-1.23)], VEGF [1.72 (0.96-2.48)], ADMA [0.19 (0.08-0.3)], AGEs [3.91 (2.36-5.45)] and Lp(a) [0.81 (0.58-1.04)] concentrations compared with controls, yet with significant between-study heterogeneity. Borderline significance (not robust in the sensitivity analyses) was detected for TNF-α [0.75 (0.07-1.44)], ET-1 [1.06 (0.52-1.59)] and fibrinogen [0.20 (0.01-0.39)], whereas no difference was detected for IL-6 [0.71 (-0.16 to 1.59)]. CONCLUSIONS Women with PCOS have increased serum concentrations of CVD risk markers compared with controls. Whether this apparent risk is translated into increased incidence of CVD in later life remains to be elucidated.
    Human Reproduction Update 05/2011; 17(6):741-60. DOI:10.1093/humupd/dmr025
Show more